Expert Interview
Delving into the NefIgArd phase 3 data on Nefecon, Calliditas' formulation of budesonide for the treatment of IgA Nephropathy
Ticker(s): CALTInstitution: Columbia University
- Academic nephrologist with expertise in glomerular diseases; Associate Professor of Medicine at Columbia University Medical Center.
- Currently manages ~50 patients with Lupus Nephritis and ~50 patients with IgAN.
- Clinical and research interests are focused on glomerular diseases; heavily involved in a variety of clinical and translational studies including the NIH-sponsored CureGN and NEPTUNE cohort studies.
How do you treat IgAN today? Anything else in the competitive landscape that is enticing?
Added By: max_adminThoughts on the MoA of Nefecon?
Added By: max_adminThoughts on Nefecon AE profile (infection risk? DVT? v. Budesonide generally)?
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
